Effect of early treatment on physical function in daily management of rheumatoid arthritis

A 5-year longitudinal study of rheumatoid arthritis patients in the national database of rheumatic diseases in Japan

Akie Hirata, Yasuo Suenaga, Tomoya Miyamura, Toshihiro Matsui, Shigeto Tohma, Eiichi Suematsu, Ohnaka Keizo, Ryoichi Takayanagi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Aim: The purpose of this study was to assess 5-year changes in physical function and factors associated with improvement among patients with rheumatoid arthritis (RA) in daily clinical practice, focusing on the effect of treatments, including biologic agents, in the early stage of disease course. Methods: The National Database of Rheumatic Diseases by iR-net in Japan (NinJa) was searched for patients with disease duration ≤ 2 years and modified health assessment questionnaire (mHAQ) > 0 between 2004 and 2007, so that 510 patients were included in the final analysis. Multivariate-logistic regression analyses were used to identify predictors of 5-year mHAQ disability score improvement. Results: Median mHAQ score was 0.40 at baseline and decreased to a median 0.17 after 5 years. Seventy-four percent of the patients were treated with methotrexate (MTX) and 25% with biologic agents, with early use of biologic agents (within 2 years of RA onset) increasing over time. Multivariate analyses identified higher baseline Disease Activity Score of 28 joints – C-reactive protein and early use of MTX (within 1 year of RA onset) and of biologic agents (within 2 years) as significantly associated with improved mHAQ; odds ratios of the early treatment were 1.83 (P = 0.01) for MTX and 2.23 (P = 0.04) for biologic agents, respectively. Conclusion: Five-year mHAQ improved in early RA patients in the NinJa database. In daily clinical management of RA, likewise in clinical trials, early administration of MTX or biologic agents is able to improve physical function outcome.

Original languageEnglish
Pages (from-to)828-835
Number of pages8
JournalInternational Journal of Rheumatic Diseases
Volume21
Issue number4
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Biological Factors
Rheumatic Diseases
Longitudinal Studies
Rheumatoid Arthritis
Japan
Databases
Methotrexate
Health
Therapeutics
C-Reactive Protein
Multivariate Analysis
Joints
Logistic Models
Odds Ratio
Regression Analysis
Surveys and Questionnaires
Clinical Trials

All Science Journal Classification (ASJC) codes

  • Rheumatology

Cite this

Effect of early treatment on physical function in daily management of rheumatoid arthritis : A 5-year longitudinal study of rheumatoid arthritis patients in the national database of rheumatic diseases in Japan. / Hirata, Akie; Suenaga, Yasuo; Miyamura, Tomoya; Matsui, Toshihiro; Tohma, Shigeto; Suematsu, Eiichi; Keizo, Ohnaka; Takayanagi, Ryoichi.

In: International Journal of Rheumatic Diseases, Vol. 21, No. 4, 01.01.2018, p. 828-835.

Research output: Contribution to journalArticle

@article{d666e646819343b1ae36d1f31240fa41,
title = "Effect of early treatment on physical function in daily management of rheumatoid arthritis: A 5-year longitudinal study of rheumatoid arthritis patients in the national database of rheumatic diseases in Japan",
abstract = "Aim: The purpose of this study was to assess 5-year changes in physical function and factors associated with improvement among patients with rheumatoid arthritis (RA) in daily clinical practice, focusing on the effect of treatments, including biologic agents, in the early stage of disease course. Methods: The National Database of Rheumatic Diseases by iR-net in Japan (NinJa) was searched for patients with disease duration ≤ 2 years and modified health assessment questionnaire (mHAQ) > 0 between 2004 and 2007, so that 510 patients were included in the final analysis. Multivariate-logistic regression analyses were used to identify predictors of 5-year mHAQ disability score improvement. Results: Median mHAQ score was 0.40 at baseline and decreased to a median 0.17 after 5 years. Seventy-four percent of the patients were treated with methotrexate (MTX) and 25{\%} with biologic agents, with early use of biologic agents (within 2 years of RA onset) increasing over time. Multivariate analyses identified higher baseline Disease Activity Score of 28 joints – C-reactive protein and early use of MTX (within 1 year of RA onset) and of biologic agents (within 2 years) as significantly associated with improved mHAQ; odds ratios of the early treatment were 1.83 (P = 0.01) for MTX and 2.23 (P = 0.04) for biologic agents, respectively. Conclusion: Five-year mHAQ improved in early RA patients in the NinJa database. In daily clinical management of RA, likewise in clinical trials, early administration of MTX or biologic agents is able to improve physical function outcome.",
author = "Akie Hirata and Yasuo Suenaga and Tomoya Miyamura and Toshihiro Matsui and Shigeto Tohma and Eiichi Suematsu and Ohnaka Keizo and Ryoichi Takayanagi",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/1756-185X.12877",
language = "English",
volume = "21",
pages = "828--835",
journal = "International Journal of Rheumatic Diseases",
issn = "1756-1841",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Effect of early treatment on physical function in daily management of rheumatoid arthritis

T2 - A 5-year longitudinal study of rheumatoid arthritis patients in the national database of rheumatic diseases in Japan

AU - Hirata, Akie

AU - Suenaga, Yasuo

AU - Miyamura, Tomoya

AU - Matsui, Toshihiro

AU - Tohma, Shigeto

AU - Suematsu, Eiichi

AU - Keizo, Ohnaka

AU - Takayanagi, Ryoichi

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Aim: The purpose of this study was to assess 5-year changes in physical function and factors associated with improvement among patients with rheumatoid arthritis (RA) in daily clinical practice, focusing on the effect of treatments, including biologic agents, in the early stage of disease course. Methods: The National Database of Rheumatic Diseases by iR-net in Japan (NinJa) was searched for patients with disease duration ≤ 2 years and modified health assessment questionnaire (mHAQ) > 0 between 2004 and 2007, so that 510 patients were included in the final analysis. Multivariate-logistic regression analyses were used to identify predictors of 5-year mHAQ disability score improvement. Results: Median mHAQ score was 0.40 at baseline and decreased to a median 0.17 after 5 years. Seventy-four percent of the patients were treated with methotrexate (MTX) and 25% with biologic agents, with early use of biologic agents (within 2 years of RA onset) increasing over time. Multivariate analyses identified higher baseline Disease Activity Score of 28 joints – C-reactive protein and early use of MTX (within 1 year of RA onset) and of biologic agents (within 2 years) as significantly associated with improved mHAQ; odds ratios of the early treatment were 1.83 (P = 0.01) for MTX and 2.23 (P = 0.04) for biologic agents, respectively. Conclusion: Five-year mHAQ improved in early RA patients in the NinJa database. In daily clinical management of RA, likewise in clinical trials, early administration of MTX or biologic agents is able to improve physical function outcome.

AB - Aim: The purpose of this study was to assess 5-year changes in physical function and factors associated with improvement among patients with rheumatoid arthritis (RA) in daily clinical practice, focusing on the effect of treatments, including biologic agents, in the early stage of disease course. Methods: The National Database of Rheumatic Diseases by iR-net in Japan (NinJa) was searched for patients with disease duration ≤ 2 years and modified health assessment questionnaire (mHAQ) > 0 between 2004 and 2007, so that 510 patients were included in the final analysis. Multivariate-logistic regression analyses were used to identify predictors of 5-year mHAQ disability score improvement. Results: Median mHAQ score was 0.40 at baseline and decreased to a median 0.17 after 5 years. Seventy-four percent of the patients were treated with methotrexate (MTX) and 25% with biologic agents, with early use of biologic agents (within 2 years of RA onset) increasing over time. Multivariate analyses identified higher baseline Disease Activity Score of 28 joints – C-reactive protein and early use of MTX (within 1 year of RA onset) and of biologic agents (within 2 years) as significantly associated with improved mHAQ; odds ratios of the early treatment were 1.83 (P = 0.01) for MTX and 2.23 (P = 0.04) for biologic agents, respectively. Conclusion: Five-year mHAQ improved in early RA patients in the NinJa database. In daily clinical management of RA, likewise in clinical trials, early administration of MTX or biologic agents is able to improve physical function outcome.

UR - http://www.scopus.com/inward/record.url?scp=85047223694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047223694&partnerID=8YFLogxK

U2 - 10.1111/1756-185X.12877

DO - 10.1111/1756-185X.12877

M3 - Article

VL - 21

SP - 828

EP - 835

JO - International Journal of Rheumatic Diseases

JF - International Journal of Rheumatic Diseases

SN - 1756-1841

IS - 4

ER -